Quantification of hemorphins in Alzheimer's disease brains

被引:30
作者
Poliak, A [1 ]
McLean, CA
Sachdev, P
Brodaty, H
Smythe, GA
机构
[1] Univ New S Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW 2052, Australia
[2] Univ Melbourne, Dept Pathol, Mol Neurobiol Lab, Melbourne, Vic, Australia
[3] Prince Wales Hosp, Inst Neuropsychiat, Sydney, NSW, Australia
[4] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia
[5] Prince Wales Hosp, Acad Dept Old Age Psychiat, Sydney, NSW, Australia
关键词
Alzheimer's disease; hemorphins; ACE inhibition;
D O I
10.1002/jnr.20020
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The hemorphins are a family of opioid receptor-binding peptides originating from the P-chain of hemoglobin and have been found at high levels within the central and peripheral nervous systems. In addition to opioid receptor binding, hemorphins have been shown to have a number of effects on the renin-angiotensin system, including inhibition of angiotensin-converting enzyme and angiotensin IV receptor binding. However, relatively few studies have examined the role of hemorphins in neurological diseases. Here we report the first study of hemorphins in Alzheimer's disease (AD) brains. Quantitative MALDI-TOF mass spectrometry was employed to assess levels of LVV and VV hemorphin-6 and -7 in 10 control and 10 AD brain tissue samples. LVV hemorphin-6 and total hemorphin levels were elevated in AD temporal neocortex but not in hippocampus, occipital lobe, or frontal lobe. The elevation of hemorphins is probably indicative of a vascular abnormality resulting from cerebral amyloid angiopathy associated with both neurodegenerative disease and aging. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:704 / 714
页数:11
相关论文
共 40 条
[1]   Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase [J].
Albiston, AL ;
McDowall, SG ;
Matsacos, D ;
Sim, P ;
Clune, E ;
Mustafa, T ;
Lee, J ;
Mendelsohn, FAO ;
Simpson, RJ ;
Connolly, LM ;
Chai, SY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48623-48626
[2]   ANGIOTENSIN CONVERTING ENZYME IN ALZHEIMERS-DISEASE - INCREASED ACTIVITY IN CAUDATE-NUCLEUS AND CORTICAL AREAS [J].
ARREGUI, A ;
PERRY, EK ;
ROSSOR, M ;
TOMLINSON, BE .
JOURNAL OF NEUROCHEMISTRY, 1982, 38 (05) :1490-1492
[3]   ANGIOTENSIN CONVERTING ENZYME DENSITY IS INCREASED IN TEMPORAL CORTEX FROM PATIENTS WITH ALZHEIMERS-DISEASE [J].
BARNES, NM ;
CHENG, CHK ;
COSTALL, B ;
NAYLOR, RJ ;
WILLIAMS, TJ ;
WISCHIK, CM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 200 (2-3) :289-292
[4]   Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin beta-chain [J].
Blishchenko, EY ;
Mernenko, OA ;
Mirkina, II ;
Satpaev, DK ;
Ivanov, VS ;
Tchikin, LD ;
Ostrovsky, AG ;
Karelin, AA ;
Ivanov, VT .
PEPTIDES, 1997, 18 (01) :79-85
[5]  
BRAAK E, 1999, EUR ARCH PSYCHIAT CL, V249
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   NOVEL OPIOID-PEPTIDES DERIVED FROM HEMOGLOBIN - HEMORPHINS [J].
BRANTL, V ;
GRAMSCH, C ;
LOTTSPEICH, F ;
MERTZ, R ;
JAEGER, KH ;
HERZ, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 125 (02) :309-310
[8]   ANGIOTENSIN-II-(3-8)-HEXAPEPTIDE AFFECTS MOTOR-ACTIVITY, PERFORMANCE OF PASSIVE-AVOIDANCE AND A CONDITIONED AVOIDANCE-RESPONSE IN RATS [J].
BRASZKO, JJ ;
KUPRYSZEWSKI, G ;
WITCZUK, B ;
WISNIEWSKI, K .
NEUROSCIENCE, 1988, 27 (03) :777-783
[9]   Anti-inflammatory drugs protect against Alzheimer disease at low doses [J].
Broe, GA ;
Grayson, DA ;
Creasey, HM ;
Waite, LM ;
Casey, BJ ;
Bennett, HP ;
Brooks, WS ;
Halliday, GM .
ARCHIVES OF NEUROLOGY, 2000, 57 (11) :1586-1591
[10]  
BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182